Use of rituximab in multiple sclerosis: current progress and future perspectives

Area of Science:

• Immunology
• Neuroscience
• Pharmacology

Background:

• Recent advances reveal crucial immunological pathways in multiple sclerosis (MS).
• Established treatments like natalizumab have transformed MS management.
• B cells play a significant role in the pathogenesis of MS.

Purpose of the Study:

• To review the role of B cells in multiple sclerosis (MS).
• To discuss the immunomodulatory pathways and therapeutic potential of rituximab in MS.
• To evaluate recent clinical data and safety aspects of rituximab for MS treatment.

Main Methods:

• Review of experimental and clinical trial data on rituximab in MS.
• Analysis of B-cell depletion mechanisms.
• Assessment of safety profiles and future treatment perspectives.

Main Results:

• Rituximab, a CD20-antibody, effectively depletes B cells implicated in MS.
• Clinical studies and case reports indicate rituximab stabilizes MS course, reducing relapses and MRI lesions.
• Successful use of rituximab in other B-cell-mediated autoimmune diseases and neuromyelitis optica (NMO).

Conclusions:

• B-cell-targeted therapy with rituximab presents a promising strategy for multiple sclerosis.
• Further research and clinical trials are warranted to establish rituximab's role in MS treatment.
• Rituximab offers a potential new therapeutic option for managing the disease course of MS.